Barchart Demo Center



Stock Screeners




Fund Screeners

Foreign Exchange



Financial Calculators

Embedded Widgets



JSON Feeds

Symbol Overview

United States|Canada

Regeneron Pharmaceuticals

Add to Portfolio
+5.86 (+1.59%)
as of 20:00 EST

Last 373.53
Change +5.86 (+1.59%)
Open 368.40
Prev. Close 367.67
Today's Range
52wk Range
Volume 935,600
Avg Volume 823,300
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
REGN +1.59% +35.11% -0.58%
DJIA +0.11% +5.04% +14.53%
S&P 500 +0.29% +6.85% +19.15%

Key Statistics

Annual EPS 18.68
Dividend Yield 0.00%
P/E Ratio 17.58
Market Capitalization, $K 40,143,980
Weighted Alpha +6.80
Standard Deviation +1.10
Profit Margin -33.60%
Beta 1.20

Growth Rates

YTD +0.01%
1-Year -3.54%
3-Year -2.95%
5-Year -14.02%
10-Year +1,420.55%


Sell Hold Buy

Recent Headlines

Regeneron Pharm Set to Possibly Pullback After

Comtex SmarTrend(R) via COMTEX - 11:56AM EST
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $368.25 to a high of $376.63. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $373.73 on volume of 318,(full story)
REGN: 373.53 (+5.86)

Sanofi and Regeneron announce intent to restructure

Globe Newswire via COMTEX - Tue Dec 10, 08:30AM EST
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara(R) (sarilumab) and Praluent(R) (alirocumab)(full story)
REGN: 373.53 (+5.86)

Regeneron and Sanofi Announce Intent to Restructure

PR Newswire via COMTEX - Tue Dec 10, 08:29AM EST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced their intent to simplify their antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) by restructuring into a royalty-based agre(full story)
REGN: 373.53 (+5.86)

First Clinical Data for REGN5458 (BCMAxCD3) Show

PR Newswire via COMTEX - Sun Dec 08, 09:00AM EST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is(full story)
REGN: 373.53 (+5.86)

Regeneron Announces Positive Topline Phase 2 Data with

PR Newswire via COMTEX - Thu Dec 05, 07:00AM EST
Results from initial 6-patient cohort show pozelimab reduced lactate dehydrogenase (LDH) to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria (PNH), utilizing a weekly subcutaneous dosing regimen(full story)
REGN: 373.53 (+5.86)